Clinical Trials Browser

Phase 2 × Neoplasm Metastasis × anlotinib × Clear all

NCT04055792 2023-06-28

Sintilimab Combined With Anlotinib as Second or Further-line Therapy for ED-SCLC

Phase 2 Completed

Neoplasm Metastasis